HarmoniaMentis
Clinical perspectives
This promotional website is managed and funded by Angelini Pharma and is intended for UK and Ireland healthcare professionals only.
Explore expert-led discussions on key aspects of epilepsy management, featuring Professor John Paul Leach, Consultant Neurologist and Senior Clinical Fellow at Angelini Pharma.
These videos provide practical insights into translating evidence into clinical practice, with the aim of improving patient outcomes.
Professor John Paul Leach
Professor John Paul Leach is a Scottish neurologist who completed his training in neurology and clinical neurophysiology in Glasgow and then Liverpool, after gaining his MD in antiepileptic drugs in 1998. He became a consultant in neurology and epilepsy in 2002, returning to his hometown of Glasgow. He has previously been a committee member for ILAE UK and the ABN, serving as President of the UK Chapter from 2014. He was a Professor of Clinical Neurology and Head of Undergraduate Medicine at the University of Glasgow. In 2023, he moved to Angelini Pharma in Rome as a full-time Senior Clinical Fellow. His current role involves working on the development of antiseizure medications and other neurological treatments.
Translating the Evidence from Pivotal Epilepsy Trials to Clinical Practice
Professor Leach discusses how data from pivotal epilepsy trials can be applied in real-world clinical settings to support informed treatment decisions and optimise patient care.
This video was recorded in September 2025.
Towards Seizure Freedom: Lessons from the BLESS Study
Professor Leach reviews real-world data from the BLESS study on adjunctive cenobamate in adults with uncontrolled focal-onset epilepsy.1,2
This video was recorded in September 2025.
Managing SUDEP Risk: Exploring Real-World Data
Professor Leach explores real-world evidence and clinical experience in managing SUDEP risk in epilepsy care.
This video was recorded in September 2025.
ABN = Association of British Neurologists; ILAE = International League Against Epilepsy; MD = Doctor of Medicine.
United Kingdom: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti–epileptic medicinal products.1
Republic of Ireland: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti–epileptic medicinal products.1
1. ONTOZRY® Summary of Product Characteristics. United Kingdom and European Union.
2. Lattanzi S, et al. BLESS Study Group. Epilepsia. 2025 Jul;66(7):2239-2252.
MAT-UKI-0317-P | March 2026
